Innovation
Prevention is the best medicine
Prevention is about innovating to change the course of disease
Scroll to explore
Ahead Together in genetics/genomics/vaccines/medicines/innovation
We get ahead of disease together by preventing and treating it with innovation in vaccines and specialty medicines. Our R&D approach combines our scientific focus on the immune system - with the use of advanced technologies.
We are working to deliver a new generation of differentiated, needed vaccines and medicines in four core therapeutic areas where we have the strongest expertise, and where significant patient need remains: infectious diseases, HIV, respiratory/immunology, and oncology.
Technology powers all aspects of our R&D. We use human genetics and functional genomics, along with artificial intelligence and machine learning (AI/ML), to deeply understand the patient, human biology, and disease mechanisms. This is leading to real breakthroughs for tackling a range of conditions, such as liver disease, or transforming HIV treatment and prevention.
We believe the powerful combination of science and technology holds the key to fundamentally transforming medical discovery for the better, making the R&D process more dynamic, improving success rates and shaping how even the most challenging diseases, like neurological conditions and cancer, can be both prevented and treated.
There’s never been a time when science and technology have formed such a powerful union as they do now. We’re able to identify drug discovery targets using genomics and AI/ML in a way that is unprecedented. We’re also able to use more approaches than ever before to design new vaccines and medicines to address the root cause of disease.
-
Our R&D investment in 2023
£6.2bn -
Major business development deals in 2023
6 -
Vaccines and medicines in the pipeline
71 -
Phase I programmes started in 2023
8
Ahead of disease together
The pillars of our innovation
Partnerships that matter
How we apply technologies
Our R&D locations
Spotlight on GSK innovation
Our pipeline
As a global biopharma leader, we invest heavily in our industry-leading pipeline of potential vaccines and specialty medicines that help us to get ahead of disease together
Therapeutic areas
The four areas of human health we focus on to get ahead of disease are: infectious diseases, HIV, respiratory/immunology, and oncology.
Our leading scientists
Meet the world-leading scientists who are uniting science, technology and talent to get ahead of disease together.
Innovation events and conferences
Hear from industry experts, explore the latest breakthroughs and network with us.
